The Global Market for Acute Myeloid Leukemia (AML) Therapeutics is Projected to Reach US$1.1 Billion by 2022

Novel Therapies in the Pipeline to Drive the Global Acute Myeloid Leukemia (AML) Therapeutics Market, According to a New Report by Global Industry Analysts, Inc.

GIA launches comprehensive analysis of industry segments, trends, growth drivers, market size, share and demand forecasts on the global Acute Myeloid Leukemia (AML) Therapeutics market. The global market for Acute Myeloid Leukemia (AML) Therapeutics is projected to reach US$1.1 billion by 2022, driven by aging population and its susceptibility to AML, rising cases of relapsed/refractory AML and new therapies in late stage clinical development.

Acute Myeloid Leukemia (AML), the most common form of leukemia worldwide, is a cancer typified by presence of immature WBCs in bone marrow without the capability to mature. The market for AML therapeutics is driven by aging population, chaining lifestyles, increasing cases of genetic mutations, and rising cases of relapsed/refractory AML. The growing incidence and prevalence, poor prognosis and lack of effective therapies make the disease fatal with low survival rate, creating significant unmet needs in the market. Chemotherapy remains the standard of care for AML, although induction therapy with chemo is associated with low efficacy, severe toxicity and side effects in many patients. With minimal improvements, excepting at dosing and scheduling levels, conventional therapy is leaving considerable opportunities for novel drugs that are safe and can extend survival. Although certain new drug candidates failed over the years due to lack of efficacy and safety, hope emerges from several novel drugs presently in clinical development that have demonstrated better efficacy than their predecessors. Immunotherapies, targeted therapies, and even novel cytotoxic chemotherapies are currently under development, which are expected to accelerate growth in the market.

Improved application of genetics of AML is a prime reason for growing litany of novel drugs under clinical trials. Insights into the genes involved in bone marrow changes have improved understanding of causes of AML and their types, thereby enabling improving targeting capabilities as seen in therapies that are in pipeline. Most promising drug classes include FLT3 inhibitors such as midostaurin and Quizartinib that have a different action mechanism compared to chemotherapy and novel chemotherapy formulations including Vyxeos and Guadecitabine, along with various other drugs that are in pivotal trials. Failures even in cases of some new breed of drugs in proving efficacy, and lower prices of gold standard generic chemotherapy, however are factors expected to restrain growth in the market.

As stated by the new market research report on Acute Myeloid Leukemia (AML) Therapeutics, the United States represents the largest market worldwide. The country also represents the fastest growing market with a CAGR of 17.4% through the analysis period led by higher awareness of the condition and the drugs that treat it, continued acceptance of existing therapeutics, willingness to adopt advanced and expensive drugs, favorable multi-payer model for oncology care and expected launch of new medications. The growth in emerging markets, particularly Asia-Pacific, is expected to be supported by increasing incidence of cancer, improving healthcare infrastructure, increasing income and higher per capita healthcare spending and rising prominence of the medical tourism trend.  

Major players covered in the report include AbbVie Inc., Agios Pharmaceuticals Inc., Amgen Inc., Astellas Pharma Inc., Astex Pharmaceuticals Inc., Celgene Corporation, CTI BioPharma Corp., Cyclacel Pharmaceuticals Inc., Daiichi Sankyo Company Limited, F. Hoffmann-La Roche AG, Immune Pharmaceuticals Inc., Janssen-Cilag Limited, Jazz Pharmaceuticals plc, MEI Pharma Inc., Novartis AG, Pfizer Inc., Seattle Genetics Inc., Stemline Therapeutics Inc., Sunesis Pharmaceuticals Inc. and Tolero Pharmaceuticals Inc., among others.

The research report titled “Acute Myeloid Leukemia (AML) Therapeutics: A Global Strategic Business Report” announced by Global Industry Analysts Inc., provides a comprehensive review of market trends, issues, drivers, mergers, acquisitions and other strategic industry activities of global companies. The report provides market estimates and projections for Acute Myeloid Leukemia (AML) Therapeutics in value terms for all major geographic markets such as US, Canada, Japan, Europe (France, Germany, Italy, UK and Rest of Europe) and Rest of World.

To connect with us, visit our LinkedIn page.

Global Industry Analysts, Inc. 6150 Hellyer Ave., San Jose CA 95138, USA, All Rights Reserved.